XORTX Therapeutics prices $1.1M (U.S.) direct offering

Mr. Allen Davidoff reports XORTX ANNOUNCES PRICING OF US$1.1 MILLION REGISTERED DIRECT OFFERING XORTX Therapeutics Inc. has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares (or common share equivalents in lieu thereof) in a registered direct offering at a purchase price of 63 U.S. cents per common share. The closing of the offering is expected to occur on or about Oct. 22, 2025, subject to the satisfaction of customary closing conditions and approval from the TSX Venture Exchange. The gross proceeds from the offering are expected to be $1.1-million (U.S.), before deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital and general corporate purposes. D. Boral Capital LLC is acting as sole placement agent for the offering. The common shares (and common share equivalents in lieu thereof) will be issued in a registered direct offering pursuant to an effective shelf registration statement on Form F-3 (file No. 333-269429) previously filed with the U.S. Securities and Exchange Commission (the SEC), under the Securities Act of 1933, as amended, and declared effective by the SEC on Feb. 3, 2023. A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC and, once filed, will be available on the SEC's website. Electronic copies of the prospectus supplement may be obtained, when available, from D. Boral Capital LLC, 590 Madison Ave., 39th floor, New York, N.Y., 10022, or by telephone at 1-212-970-5150, or by e-mail at [email protected]. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) the company's lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, the company is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. We seek Safe Harbor.